biliary tract cancer
Oncology · 2023–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ivosidenib Treatment of locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation in patients who have progressed on at least one prior line of systemic… | Nov 2024 | Recommended with restriction | 12 individuals Pancare Foundation · Liver Foundation · Cholangiocarcinoma Foundation Australia · Medical Oncology Group |
| durvalumab First-line treatment of patients with locally advanced, metastatic, or recurrent biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic… | Jul 2023 | Recommended | input received Medical Oncology Group |
| durvalumab First-line treatment of patients with advanced biliary tract cancer (locally advanced unresectable, metastatic, or recurrent disease), in combination with… | Mar 2023 | Not recommended | 4 individuals Cholangiocarcinoma Foundation Australia · Rare Cancers Australia · Australasian Gastro Intestinal Trials Group · PanCare Foundation · Medical Oncology Group |
Who spoke
Medical Oncology Group · Cholangiocarcinoma Foundation Australia · Pancare Foundation · Liver Foundation · Rare Cancers Australia · Australasian Gastro Intestinal Trials Group · PanCare Foundation
What the PBS pays
$176M in government benefit over 2024–25, across 16,460 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| durvalumab | $175.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 5 technologies for this condition, recommending 4 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| zanidatamabZanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment | TA1153 | recommended restricted | 2026-05 |
| pembrolizumabPembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | terminated | 2024-04 |
| ivosidenibIvosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | recommended restricted | 2024-01 |
| durvalumabDurvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | recommended restricted | 2024-01 |
| pemigatinibPemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | recommended restricted | 2021-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.